Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 103

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 103
---
 could also make it more difficult for us to attract and retain qualified
members of our Board of Directors.

As a foreign private issuer, we are not required to comply with many of the corporate governance standards of NASDAQ applicable to companies incorporated in the United States.

Our Board of Directors is
required to maintain an audit committee comprised solely of three or more directors satisfying the independence standards of NASDAQ applicable
to audit committee members. As a foreign private issuer, however, we are not required to comply with most of the other corporate governance
rules of NASDAQ, including the requirement to maintain a majority of independent directors, and nominating and compensation committees
of our Board of Directors comprised solely of independent directors. Although United Kingdom corporate governance rules which we abide
by have comparable requirements, holders of Depositary Shares may not be afforded the benefits of the corporate governance standards of
NASDAQ to the same extent applicable to companies incorporated in the United States.

Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings.

Under English law, shareholders
usually have preemptive rights to subscribe on a pro rata basis in the issuance of new shares for cash. The exercise of preemptive rights
by certain shareholders not resident in the United Kingdom may be restricted by applicable law or practice in the United Kingdom and overseas
jurisdictions. We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we
cannot make rights available to shareholders in the United States unless we register the rights and the securities to which the rights
relate under the Securities Act or an exemption from the registration requirements is available. Also, under the deposit agreement, the
depositary bank will not make rights available to Depositary Share holders unless either both the rights and any related securities are
registered under the Securities Act, or the distribution of them to Depositary Share holders is exempted from registration under the Securities
Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause
such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under
the Securities Act. If the Depositary does not distribute the rights, it may, under the deposit agreement, either sell them, if possible,
or allow them to lapse. Accordingly, Depositary Share holders may be unable to participate in our rights offerings and may experience
dilution in their holdings. We are also permitted under English law to